Skip to main navigation Skip to search Skip to main content

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

  • on behalf of the 1703 study investigators

Research output: Contribution to journal › Article › peer-review

145   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science